Published in:
01-04-2018 | Correction
Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors
Published in: Breast Cancer Research and Treatment | Issue 2/2018
Login to get accessExcerpt
In the original publication, the values provided for the isoflavone and glucosinolate intake variables were incorrectly labeled in Table 1. The correct values of 6.3 mg/day for isoflavone intake, and 20.4 mg/day and 50.1 mg/day for glucosinolate intake are provided in this erratum. Under the “Statistical Analysis” section, second paragraph, the values in the 11th line “…time since diagnosis (< 4, 3–36, and ≥ 36 months)…” was mislabeled. The correct values were “< 24, 24–36, and > 36 months”.
Table 1
Population characteristics
|
Total population
|
Non-Hispanic White
|
Chinese American
|
|
|---|---|---|---|
|
Total N (%)
|
365 (100)
|
173 (47.4)
|
192 (52.6)
|
|
Age in years (mean, SD)
|
57.1 (10.4)
|
57.2 (10.5)
|
56.9 (10.4)
|
|
Menopausal status (N, %)
|
|||
|
Premenopause
|
47 (13.0)
|
21 (12.3)
|
26 (13.7)
|
|
Induced menopause
|
61 (16.9)
|
30 (17.5)
|
31 (16.3)
|
|
Perimenopause
|
81 (22.4)
|
35 (20.5)
|
46 (24.2)
|
|
Postmenopause
|
172 (47.6)
|
85 (49.7)
|
87 (45.8)
|
|
BMI (kg/m2) (mean, SD)
|
24.0 (4.4)
|
25.2 (5.1)
|
22.9 (3.1)
|
|
Physical activity (N, %)a
|
|||
|
Active
|
110 (30.1)
|
77 (44.5)
|
33 (17.2)
|
|
Minimally active
|
136 (37.3)
|
58 (33.5)
|
78 (40.6)
|
|
Inactive
|
119 (32.6)
|
38 (22.0)
|
81 (42.2)
|
|
Cancer stage (N, %)
|
|||
|
Stage 0
|
110 (30.1)
|
64 (37.0)
|
46 (24.0)
|
|
Stage I
|
166 (45.4)
|
77 (44.5)
|
89 (46.4)
|
|
Stage II
|
47 (12.9)
|
22 (12.7)
|
25 (13.0)
|
|
Stage III
|
42 (11.5)
|
10 (5.8)
|
32 (16.7)
|
|
Endocrine therapy (N, %)
|
|||
|
None
|
148 (40.8)
|
74 (42.8)
|
74 (38.5)
|
|
Tamoxifen
|
126 (34.5)
|
60 (34.7)
|
66 (34.4)
|
|
Aromatase inhibitor
|
91 (24.9)
|
39 (22.5)
|
52 (27.1)
|
|
Lumpectomy (N, %)
|
|||
|
No
|
141 (38.6)
|
59 (34.1)
|
82 (42.5)
|
|
Yes
|
224 (61.4)
|
114 (65.9)
|
110 (57.3)
|
|
Mastectomy (N, %)
|
|||
|
No
|
228 (62.5)
|
114 (65.9)
|
114 (59.4)
|
|
Yes
|
137 (37.5)
|
59 (34.1)
|
78 (40.6)
|
|
Chemotherapy (N, %)
|
|||
|
No
|
257 (76.3)
|
127 (80.4)
|
130 (72.6)
|
|
Yes
|
80 (23.7)
|
31 (19.6)
|
49 (27.4)
|
|
Radiation therapy (N, %)
|
|||
|
No
|
198 (54.2)
|
88 (50.9)
|
110 (57.3)
|
|
Yes
|
167 (45.8)
|
85 (49.1)
|
82 (42.7)
|
|
Time since diagnosis (N, %)
|
|||
|
< 24 months
|
108 (29.6)
|
48 (27.7)
|
60 (31.3)
|
|
24–36 months
|
111 (30.4)
|
49 (28.3)
|
62 (32.3)
|
|
> 36 months
|
146 (40.0)
|
76 (43.9)
|
70 (36.5)
|
|
Estrogen receptor (N, %)
|
|||
|
Positive
|
227 (62.2)
|
109 (63.0)
|
118 (61.5)
|
|
Negative
|
49 (13.4)
|
19 (11.0)
|
30 (15.6)
|
|
Unknown
|
89 (24.4)
|
45 (26.0)
|
44 (22.9)
|
|
Progesterone receptor (N, %)
|
|||
|
Positive
|
196 (53.7)
|
91 (52.6)
|
105 (54.7)
|
|
Negative
|
80 (21.9)
|
37 (21.4)
|
43 (22.4)
|
|
Unknown
|
89 (24.4)
|
45 (26.0)
|
44 (22.9)
|
|
HER2 (N, %)
|
|||
|
Positive
|
44 (12.1)
|
18 (10.4)
|
26 (13.5)
|
|
Negative
|
167 (45.8)
|
74 (42.8)
|
93 (48.4)
|
|
Unknown
|
154 (42.2)
|
81 (46.8)
|
73 (38.0)
|
|
Soy products (N, %)b
|
|||
|
No intake
|
104 (28.5)
|
73 (42.2)
|
31 (16.1)
|
|
> 0–< 24.0 g/day
|
131 (35.9)
|
65 (37.6)
|
66 (34.4)
|
|
≥ 24.0 g/day
|
130 (35.6)
|
35 (20.2)
|
95 (49.5)
|
|
Isoflavones (N, %)b
|
|||
|
No intake
|
104 (28.5)
|
73 (42.2)
|
31 (16.1)
|
|
>0–< 6.3 mg/day
|
129 (35.3)
|
62 (35.8)
|
67 (34.9)
|
|
≥ 6.3 mg/day
|
132 (36.2)
|
38 (22.0)
|
94 (49.0)
|
|
Cruciferous vegetables (N, %)b
|
|||
|
< 33.0 g/day
|
121 (33.2)
|
77 (44.5)
|
44 (22.9)
|
|
≥ 33.0–< 70.8 g/day
|
120 (32.9)
|
58 (33.5)
|
62 (32.3)
|
|
≥ 70.8 g/day
|
124 (33.9)
|
38 (22.0)
|
86 (44.8)
|
|
Glucosinolates (N, %)b
|
|||
|
≤ 20.4 mg/day
|
121 (33.2)
|
70 (40.5)
|
51 (26.6)
|
|
> 20.4–< 50.1 mg/day
|
120 (32.9)
|
55 (31.8)
|
65 (33.9)
|
|
≥ 50.1 mg/day
|
124 (33.9)
|
48 (27.7)
|
76 (39.6)
|